Having trouble accessing articles? Reset your cache.

Mammoth eyes CRISPR-based therapeutics with new funding

CRISPR company Mammoth looks beyond diagnostics with Decheng Capital-led $45M series B

With a $45 million series B round led by Decheng Capital, Mammoth Biosciences is capitalizing on its IP position around an alternative CRISPR enzyme and expanding its gene editing capabilities beyond diagnostics into a range of therapeutic applications.

Mayfield, NFX, Verily and Brook Byers also participated in the round, which brings the company’s total funding

Read the full 555 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE